SynBiotic SE's Revenue Forecasted to Triple by 2027 Amid Cannabis Market Growth

SynBiotic SE is set to experience significant revenue growth, aiming to triple earnings by 2027. The company targets the expanding medical cannabis and industrial hemp markets, seen as billion-euro opportunities. These sectors are buoyed by growing legalization and social acceptance of cannabis in medical care. SynBiotic's diverse product range, including cannabis flowers and high-purity extracts, positions it advantageously.

The forecast projects a rise in the global medical cannabis market from EUR 4.5 billion in 2024 to EUR 62 billion by 2030. Industrial hemp also anticipates growth, with expectations of a market tripling by 2030. SynBiotic is poised to benefit from regulatory advances and increasing demand for hemp and CBD products.

The company forecasts consolidated revenue reaching EUR 48 million by 2027, representing a threefold increase. SynBiotic plans to achieve positive EBITDA by 2026, with a strategy bolstered by regulatory foresight and robust market positioning.